Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.50 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.48 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135614 | 0.92 | CHRNA10 (0.50) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL6133029 | 0.88 | CHRNA10 (0.44) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL6132263 | 0.87 | CHRNA10 (0.43) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL6134370 | 0.86 | CHRNA10 (0.52) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL20346944 | 0.78 | KDM4E (0.53) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL7331216 | 0.78 | HRH3 (0.56) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL6538555 | 0.78 | HRH3 (0.56) | HRH3CHRNA10CHRNA9KDM4ETP53 | |
| SCHEMBL11617940 | 0.78 | HRH3 (0.43) | HRH3KDM4EHRH1HRH2 | |
| SCHEMBL19002069 | 0.76 | HRH3 (0.48) | HRH3TP53 | |
| SCHEMBL16447595 | 0.76 | HRH3 (0.51) | HRH3CHRNA10CHRNA9KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | HRH3 1440/4885CHRNA10 4186/4885CHRNA9 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.